Results 111 to 120 of about 4,537,045 (350)
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Retracted: Active Compliance Control System for Intelligent Inspection Robot in Power Room
Journal of Control Science and Engineering
doaj +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop +10 more
wiley +1 more source
Retracted: Driving Detection Based on the Multifeature Fusion
Journal of Control Science and Engineering
doaj +1 more source
Engineering Design for Noise Control [PDF]
G. C. Maling, Roger J. Sawley
openalex +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
Principles and applications of quantum control engineering. [PDF]
Gough JE.
europepmc +2 more sources
Journal of Control Science and Engineering
doaj +1 more source

